Sanofi Ventures led a $70m Series A round in Matchpoint Therapeutics, a biotechnology company founded to leverage the power of covalency for the discovery of precision small molecule medicines, with participation from Vertex Ventures HC, Digitalis Ventures and Alexandria Venture Investments. "We created Matchpoint to harness the powerful properties of covalency and enable the targeting of disease-causing proteins otherwise unamenable to small molecule intervention. We believe the immunology space is greatly underserved by current small molecule therapies and are excited by the potential of our proprietary platform to deliver highly specific covalent medicines for several of its most important and difficult targets," Andre Turenne, Matchpoint President and CEO.